Halozyme Therapeutics Inc (HALO) Institutional Ownership Tracker (Q2 2026)

HALO ranks #824 out of 37503 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

668 institutions disclose a position in HALO, but none treat it as a major bet — even Snyder Capital Management L P, its most concentrated holder, allocates just 3.2% of its own portfolio to it.

Boston Partners has added to its HALO position for two straight quarters, increasing it by $183.7M to reach $216.8M today.

Israel Englander has trimmed its HALO position for two straight quarters, cutting it by $100.3M while still holding $1.6M.

HALO is up 1.8% today, and institutions have been net buyers of $1.2B this quarter — today's price move and the underlying institutional flow are pointing the same direction.

HALO posted net income of $413.6M over the trailing twelve months, and currently trades at a P/E of 32.9.

• Profitable — net income of $413.6M over the trailing twelve months
• Revenue grew 41.2% year over year
• Net income declined year over year, from $557.3M to $413.6M
• Generated $651.6M in positive operating cash flow
• Current ratio of 4.66x — enough short-term assets to cover short-term liabilities
• Liabilities run 50.73x equity — a highly leveraged balance sheet worth noting